The Indian pharma sector is poised to turn a corner on the back of excellent growth in first nine months of 2006-7.

This selection of research reports gives information and opinions on companies and industries.

Two years after it slammed into a US regulatory wall, Ranbaxy Laboratories, under its Japanese owners, is working the hard way to be back among the stars.

Piramal's domestic formulations business becomes the latest—and most expensive—acquisition of an Indian drug business by a global pharma major. As the stakes get higher, who's next?

Most of our earlier start-up listers thrive, except for a few that stumbled.

For most of its 40 years, Lupin seemed to be just another Indian pharma company trying to make hay in the US generics market. Today, it is a global generics firm to reckon with, taking on giant Teva on the value-creation front.

There’s clearly a healthy jostle for space in our monthly ranking of “India’s Most Watched Ads” as it’s not always the big spending FMCG sector that tops the most watched list.

By refocussing its strategies, Natco Pharma has pulled back from the brink of bankruptcy to power ahead in cancer drugs. Now it is looking for niche areas globally. Can it scale up and take on global competition?

The just-concluded IPL 2 looks set to usher in a vigorous engagement between Indian and South African businesses.

Indian pharma companies say they are geared to meet the global demand for the antidote to H1N1 infection.

In businesses, big or small, ranging from manufacturing to music, the fight for intellectual property is getting intense. Neglect it and you could be out of business.

Close to half of the cream of India Inc. prefers to have lesser-known auditors.

After years of rollicking appreciation, companies that make up the BT 500 are going through one of their toughest phases in a long, long time. As stocks get mercilessly hammered, this may just be the time when the men are separated from the boys. Virendra Verma reports.

Drugs, diagnostics, real estate, private equity and glass may seem a motley bunch of businesses, but it doesn’t matter how diverse your portfolio is if you can emerge top dog. And it’s leadership that Ajay Piramal is aiming for, reports S. Layak.

After Daiichi Sankyo’s purchase of Ranbaxy Labs, Teva Pharma, the world’s largest generics company, acquired Barr Pharma, the US’ fourth largest generics firm. There are two questions on pharma analysts’ lips these days: Who’s next? Are Indian generics players targets for pharma MNCs?

Appointed: R.S. Pandey, as the new Petroleum Secretary. He replaces M.S. Srinivasan, who retires on July 31. Pandey, a 1972-batch IAS officer from the Nagaland cadre, is the Steel Secretary at present. Pandey will have a 17-month stint as the Secretary, Ministry of Petroleum and Natural Gas.

The takeover of India’s best-known drug maker, Ranbaxy Laboratories, by Japanese innovator company, Daiichi Sankyo, may have evoked a sense of disbelief all around.

A healthy dose of pharma stocks in your portfolio can be a good defensive strategy in this volatile market.